Comments on Topical Antifungal Drugs TFM
Executive Summary
In recent comments on the Tentative Final Monograph for OTC topical antifungals, the Nonprescription Drug Manufacturers Association asked that FDA state in the preamble to the Final Monograph "that new combinations will be considered if new data are submitted." NDMA and Schering-Plough in separate comments requested that FDA not classify "claims regarding speed of symptomatic relief and onset of fungicidal activity provided by antifungals" as Category II, but rather consider them outside the scope of the monograph. NDMA and Schering also proposed that FDA shorten the directions for use and warnings in labeling of such products.
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.